Le Lézard
Classified in: Health, Science and technology
Subjects: Personnel, Share Issue

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 9, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 14,500 shares of Puma common stock to three new non-executive employees.

The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, May 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.


These press releases may also interest you

at 05:16
PLDT reinforces its lead among local carriers with the most number of Philippine-terminating cables as it activates the US-Transpacific Jupiter cable system by July this year, and is expected to further enhance delivery of services and improve...

at 05:15
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Large Format Printers - Global Market Trajectory & Analytics". The report presents fresh perspectives on...

at 05:10
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Large Format Displays (LFD) - Global Market Trajectory & Analytics". The report presents fresh perspectives on...

at 05:08
Over the past 25 years, since its return to the motherland, Hong Kong, as a special administrative region of China, has remained one of the most dynamic cities in the world. Meanwhile, China's decades-long drive for reform and opening up has stridden...

at 05:05
Soracom, Inc., a global provider of advanced Internet of Things (IoT) connectivity, today announced that ThingsMatrix, an experienced IoT solutions provider that offers full turnkey services, has joined the Soracom Partner Space ? a growing ecosystem...

at 05:05
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Infrastructure Solution and Integration Services - Global Market Trajectory & Analytics". The report presents...



News published on 11 may 2022 at 17:35 and distributed by: